Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt 0.24
ZTS's Cash to Debt is ranked higher than
53% of the 1159 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.17 vs. ZTS: 0.24 )
ZTS' s 10-Year Cash to Debt Range
Min: 0.14   Max: 9999
Current: 0.24

0.14
9999
Equity to Asset 0.20
ZTS's Equity to Asset is ranked lower than
54% of the 1084 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.58 vs. ZTS: 0.20 )
ZTS' s 10-Year Equity to Asset Range
Min: 0.14   Max: 0.65
Current: 0.2

0.14
0.65
Interest Coverage 8.07
ZTS's Interest Coverage is ranked higher than
54% of the 613 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 120.76 vs. ZTS: 8.07 )
ZTS' s 10-Year Interest Coverage Range
Min: 2.3   Max: 13.28
Current: 8.07

2.3
13.28
F-Score: 8
Z-Score: 4.34
M-Score: -2.62
WACC vs ROIC
7.38%
16.05%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) 19.73
ZTS's Operating margin (%) is ranked higher than
90% of the 1110 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.84 vs. ZTS: 19.73 )
ZTS' s 10-Year Operating margin (%) Range
Min: -4.53   Max: 19.73
Current: 19.73

-4.53
19.73
Net-margin (%) 12.18
ZTS's Net-margin (%) is ranked higher than
84% of the 1110 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.50 vs. ZTS: 12.18 )
ZTS' s 10-Year Net-margin (%) Range
Min: -3.62   Max: 12.18
Current: 12.18

-3.62
12.18
ROE (%) 48.98
ZTS's ROE (%) is ranked higher than
99% of the 1139 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.62 vs. ZTS: 48.98 )
ZTS' s 10-Year ROE (%) Range
Min: 11.26   Max: 51.8
Current: 48.98

11.26
51.8
ROA (%) 8.94
ZTS's ROA (%) is ranked higher than
86% of the 1170 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.52 vs. ZTS: 8.94 )
ZTS' s 10-Year ROA (%) Range
Min: 7.28   Max: 8.86
Current: 8.94

7.28
8.86
ROC (Joel Greenblatt) (%) 32.66
ZTS's ROC (Joel Greenblatt) (%) is ranked higher than
87% of the 1165 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.08 vs. ZTS: 32.66 )
ZTS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 25.88   Max: 36.32
Current: 32.66

25.88
36.32
Revenue Growth (3Y)(%) 4.00
ZTS's Revenue Growth (3Y)(%) is ranked lower than
88% of the 940 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.80 vs. ZTS: 4.00 )
ZTS' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 8.4
Current: 4

0
8.4
EBITDA Growth (3Y)(%) 21.40
ZTS's EBITDA Growth (3Y)(%) is ranked lower than
97% of the 851 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.70 vs. ZTS: 21.40 )
ZTS' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 36.2
Current: 21.4

0
36.2
EPS Growth (3Y)(%) 33.30
ZTS's EPS Growth (3Y)(%) is ranked lower than
102% of the 809 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.70 vs. ZTS: 33.30 )
ZTS' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: 66.2
Current: 33.3

0
66.2
» ZTS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

ZTS Guru Trades in Q3 2014

Bill Ackman 5,536,862 sh (New)
John Keeley 79,504 sh (+6.71%)
Robert Olstein 178,000 sh (unchged)
Vanguard Health Care Fund 10,798,417 sh (unchged)
Pioneer Investments 2,203,980 sh (unchged)
Joel Greenblatt Sold Out
Jean-Marie Eveillard 2,174,162 sh (-0.13%)
Ruane Cunniff 173,322 sh (-0.14%)
RS Investment Management 2,491,074 sh (-2.27%)
George Soros 4,031,735 sh (-8.09%)
Mario Gabelli 217,980 sh (-10.29%)
» More
Q4 2014

ZTS Guru Trades in Q4 2014

Jim Simons 650,500 sh (New)
Steven Cohen 1,718,300 sh (New)
Bill Ackman 41,569,646 sh (+650.78%)
Mario Gabelli 626,893 sh (+187.59%)
George Soros 4,106,735 sh (+1.86%)
Ruane Cunniff 173,423 sh (+0.06%)
Bill Ackman 41,823,145 sh (unchged)
Pioneer Investments 2,202,773 sh (-0.05%)
Vanguard Health Care Fund 9,178,657 sh (-15.00%)
Robert Olstein 141,000 sh (-20.79%)
John Keeley 62,164 sh (-21.81%)
Jean-Marie Eveillard 820,467 sh (-62.26%)
RS Investment Management 212,262 sh (-91.48%)
» More
Q1 2015

ZTS Guru Trades in Q1 2015

Bill Ackman 41,823,145 sh (unchged)
Mario Gabelli 614,785 sh (-1.93%)
Vanguard Health Care Fund 6,175,407 sh (-32.72%)
» More
2015

ZTS Guru Trades in 2015

Bill Ackman 41,823,145 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with ZTS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 39.40
ZTS's P/E(ttm) is ranked higher than
79% of the 1281 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.00 vs. ZTS: 39.40 )
ZTS' s 10-Year P/E(ttm) Range
Min: 27.31   Max: 42.59
Current: 39.4

27.31
42.59
Forward P/E 23.75
ZTS's Forward P/E is ranked higher than
81% of the 1281 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. ZTS: 23.75 )
N/A
PE(NRI) 39.10
ZTS's PE(NRI) is ranked higher than
81% of the 1281 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 68.20 vs. ZTS: 39.10 )
ZTS' s 10-Year PE(NRI) Range
Min: 27.31   Max: 42.59
Current: 39.1

27.31
42.59
P/B 17.50
ZTS's P/B is ranked lower than
59% of the 1281 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.24 vs. ZTS: 17.50 )
ZTS' s 10-Year P/B Range
Min: 12.65   Max: 24.37
Current: 17.5

12.65
24.37
P/S 4.70
ZTS's P/S is ranked higher than
55% of the 1281 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.24 vs. ZTS: 4.70 )
ZTS' s 10-Year P/S Range
Min: 3.11   Max: 5.03
Current: 4.7

3.11
5.03
PFCF 51.80
ZTS's PFCF is ranked higher than
80% of the 1281 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3458.60 vs. ZTS: 51.80 )
ZTS' s 10-Year PFCF Range
Min: 25.57   Max: 90.29
Current: 51.8

25.57
90.29
POCF 36.61
ZTS's POCF is ranked higher than
77% of the 1281 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 44.77 vs. ZTS: 36.61 )
ZTS' s 10-Year POCF Range
Min: 21.59   Max: 41.99
Current: 36.61

21.59
41.99
EV-to-EBIT 26.75
ZTS's EV-to-EBIT is ranked higher than
81% of the 1281 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 46.13 vs. ZTS: 26.75 )
ZTS' s 10-Year EV-to-EBIT Range
Min: 20.9   Max: 28.5
Current: 26.75

20.9
28.5
Current Ratio 3.19
ZTS's Current Ratio is ranked higher than
80% of the 1155 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.10 vs. ZTS: 3.19 )
ZTS' s 10-Year Current Ratio Range
Min: 2.37   Max: 3.19
Current: 3.19

2.37
3.19
Quick Ratio 2.00
ZTS's Quick Ratio is ranked higher than
76% of the 1155 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.60 vs. ZTS: 2.00 )
ZTS' s 10-Year Quick Ratio Range
Min: 1.35   Max: 2
Current: 2

1.35
2
Days Inventory 281.54
ZTS's Days Inventory is ranked higher than
57% of the 1281 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 153.39 vs. ZTS: 281.54 )
ZTS' s 10-Year Days Inventory Range
Min: 117.43   Max: 288.46
Current: 281.54

117.43
288.46
Days Sales Outstanding 74.75
ZTS's Days Sales Outstanding is ranked higher than
76% of the 1281 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 90.94 vs. ZTS: 74.75 )
ZTS' s 10-Year Days Sales Outstanding Range
Min: 74.75   Max: 91.07
Current: 74.75

74.75
91.07

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.70
ZTS's Dividend Yield is ranked lower than
66% of the 686 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.32 vs. ZTS: 0.70 )
ZTS' s 10-Year Dividend Yield Range
Min: 0.21   Max: 0.94
Current: 0.7

0.21
0.94
Dividend Payout 0.25
ZTS's Dividend Payout is ranked higher than
88% of the 1281 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. ZTS: 0.25 )
ZTS' s 10-Year Dividend Payout Range
Min: 0.19   Max: 0.25
Current: 0.25

0.19
0.25
Yield on cost (5-Year) 0.70
ZTS's Yield on cost (5-Year) is ranked lower than
68% of the 693 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.55 vs. ZTS: 0.70 )
ZTS' s 10-Year Yield on cost (5-Year) Range
Min: 0.21   Max: 0.94
Current: 0.7

0.21
0.94
Share Buyback Rate -0.10
ZTS's Share Buyback Rate is ranked lower than
108% of the 768 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -1.60 vs. ZTS: -0.10 )
ZTS' s 10-Year Share Buyback Rate Range
Min: 0   Max: -0.1
Current: -0.1

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.30
ZTS's Price/Median PS Value is ranked higher than
75% of the 1281 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.50 vs. ZTS: 1.30 )
ZTS' s 10-Year Price/Median PS Value Range
Min: 1   Max: 1.26
Current: 1.3

1
1.26
Earnings Yield (Greenblatt) 3.70
ZTS's Earnings Yield (Greenblatt) is ranked higher than
76% of the 1155 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.80 vs. ZTS: 3.70 )
ZTS' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.5   Max: 4.8
Current: 3.7

3.5
4.8

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:ZOE.Germany,
Zoetis Inc was incorporated in Delaware in July 2012. It is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. It markets products across four regions: the United States, Europe/Africa/Middle East, Canada/Latin America and Asia/Pacific; eight core species: the livestock species of cattle, swine, poultry, sheep and fish, and the companion animal species of dogs, cats and horses; and five product categories: anti-infectives - products that prevent, kill or slow the growth of bacteria, fungi or protozoa; vaccines - biological preparations that help prevent diseases of the respiratory, gastrointestinal and reproductive tracts or induce a specific immune response; parasiticides - products that prevent or eliminate external and internal parasites such as fleas, ticks and worms; medicated feed additives; and other pharmaceutical products - pain and sedation, oncology, antiemetic, allergy and dermatology; and reproductive products. The Company organizes and operates its business in four segments: the United States, Europe/Africa/Middle East, Canada/Latin America and Asia/Pacific. The Company sells its livestock products directly to a diverse set of livestock producers, including beef and dairy farmers as well as pork, poultry and aquaculture operations, and to veterinarians, third-party veterinary distributors and retail outlets that typically then sell the products to livestock producers. It primarily sells its companion animal products to veterinarians or to third-party veterinary distributors that typically then sell its products to veterinarians, and in each case veterinarians then typically sell its products to pet owners. Its primary competitors include animal health medicines and vaccines companies such as Merck Animal Health, the animal health division of Merck & Co., Inc. (formerly known as Intervet/Schering-Plough); Merial, the animal health division of Sanofi S.A.; Elanco, the animal health division of Eli Lilly and Company; Bayer Animal Health, the animal health division of Bayer AG; Novartis Animal Health, the animal health division of Novartis AG; and Boehringer Ingelheim Animal Health, the animal health division of Boehringer Ingelheim GmbH. In addition, it competes with hundreds of other animal health product producers throughout the world.
» More Articles for ZTS

Headlines

Articles On GuruFocus.com
Bill Ackman is keeping on buying Zoetis Feb 24 2015 
Activist Investor Bill Ackman's Newest Additions to His Portfolio Feb 18 2015 
Feeling Good With This Med Company Jan 20 2015 
2015 - First Half Jan 01 2015 
Zoetis in a Growing Global Animal Health Industry Dec 03 2014 
Ackman’s Pershing Group Buys Stake in Zoetis Nov 13 2014 
Activist Bill Ackman Buys Big Stake In Animal Healthcare Company Zoetis Nov 12 2014 
Zoetis Will Benefit from Industry Trends Oct 07 2014 
Guru Stocks at 52-Week Lows: HMC, NMR, SDRL, ZTS, BBBY Apr 21 2014 
Morning Coffee: Widely Held Guru Stocks Near 52-Week Lows Apr 10 2014 

More From Other Websites
[$$] Zoetis Won’t Tame Pharma M&A May 05 2015
[$$] Zoetis Lowers 2015 Revenue Outlook, Unveils Cost-Cutting Effort May 05 2015
Mylan Q1 Mixed; Abiomed, Mallinckrodt, Zoetis Beat May 05 2015
Zoetis Beats on Q1 Earnings, Revenue Guidance Lowered - Analyst Blog May 05 2015
Zoetis to cut up to 2,500 jobs, shut storage units May 05 2015
Abiomed, Mallinckrodt, Zoetis Beat Q1 Estimates May 05 2015
Zoetis to Cut Up to 2,500 Jobs After Pressure From Bill Ackman May 05 2015
Zoetis Reports First Quarter 2015 Results and Announces Comprehensive Operational Efficiency... May 05 2015
Zoetis (ZTS) Beats on Q1 Earnings, Updates 2015 View - Tale of the Tape May 05 2015
Zoetis to reduce operations in Venezuela, considers selling plants May 05 2015
Zoetis tops 1Q profit forecasts May 05 2015
Zoetis tops 1Q profit forecasts May 05 2015
Zoetis to Cut $300 Million in Costs After Ackman’s Pressure May 05 2015
7:12 am Zoetis beats by $0.04, reports revs in-line; guides FY15 EPS in-line, revs below consensus;... May 05 2015
Q1 2015 Zoetis Inc Earnings Release - Before Market Open May 05 2015
ZOETIS INC. Files SEC form 8-K, Results of Operations and Financial Condition May 05 2015
Zoetis Reports First Quarter 2015 Results and Announces Comprehensive Operational Efficiency... May 05 2015
Will Zoetis (ZTS) Earnings Disappoint Expectation in Q1? - Analyst Blog May 04 2015
U.S. stocks rose moderately... May 04 2015
Zoetis (ZTS) Stock Climbing Before Tomorrow’s Earnings Release May 04 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK